

14th International

MOLECULAR MEDICINE Tri-Conference

Conference Dates: February 27 - March 2, 2007

Exhibit Dates: February 28 - March 1, 2007

Moscone North Convention Center • San Francisco, CA


BRIDGING BIOLOGY CHEMISTRY & BUSINESS

- 1 **Pathway Analysis**
- 2 **Global Strategies Executive Summit**
- 3 **Mastering Medicinal Chemistry**
- 4 **Preclinical Development**
- 5 **Molecular Diagnostics**
- 6 **Commercializing Stem Cells**
- 7 **Clinical Trials in India & Asia**
- 8 **Trends in Drug Safety**
- 9 **Cancer Molecular Markers**

**Access to
all 9 Tracks
One Price!**

Book Early!

The first 50 to register by October 27 will receive a copy of G. Steven Burill's Biotech 2006 - Life Sciences Book. (See details on page 2)



Plus! Save up to \$350!

Premier Sponsors:



Corporate Sponsors:



Co-Sponsor:

THE WALL STREET JOURNAL.

Lead Sponsoring Publications:



Cambridge Healthtech Institute

250 First Avenue, Suite 300, Needham, MA 02494 • Phone: 781-972-5400 • Fax: 781-972-5425 • Toll-free in the U.S. 888-999-6288

www.Tri-Conference.com



Tenth Annual

The Biotech Pharma Partnership

Part I: Trends in Alliances, Collaborations, Acquisitions, and Other Sources of Capital: Executive Lectures and Moderated Panel • 8-11:30am

Distinguished Faculty and Advisors:

Wendy Benson, Ph.D., Senior Director, Business Development, **Roche Molecular Diagnostics**
 Arthur H. Bertelsen, Ph.D., Executive Director, Discovery Collaborations & Technology Licensing, **Schering-Plough Research Institute**
 T. (Teo) Forcht Dag, MD, MPH, MBA, FACS, FCCM, **HLM Venture Partners & Harvard-MIT Division of Health Sciences and Technology (HST) Faculty**
 Jack DeForrest, Ph.D., Vice President of Technology Licensing, Product Acquisition and Licensing, **GE Healthcare**
 Kendra B. Eager, Ph.D., Assistant. Vice President, Alliance Management, **Wyeth Global Business Development**
 Cynthia Grant, Ph.D., Associate Global Alliance Director, Global Sciences and Information, **AstraZeneca Pharmaceuticals**
 Stefanie Hansen, J.D., Director, Strategic Alliances, **Pfizer Global Research and Development**
 Robert C. Hockney, Ph.D., Director, Global Discovery Alliances, GSI, **AstraZeneca R&D**
 Rosemarie Hunziker, Ph.D., Director, Technology Development and Industrial Relations, Center for Biotechnology and Innovation, **National Institute of Dental and Craniofacial Research, National Institutes of Health**
 Jeremy Levin, D. Phil, MB. Bchir, Global Head, Business Development and Strategic Alliances, **Novartis**
 Kelly P. Longo, Ph.D., Director, Strategic Alliances, **Pfizer Inc.**
 John Iwanicki, Patent Attorney, Senior Partner, **Banner & Witcoff, Ltd.**
 Joan Lasota, Ph.D., Senior Director Alliance Management, **Merck & Co.**
 Michael O. Ransom, Ph.D., Alliance Manager, Eli Lilly & Co., Lilly Corporate Center, **Lilly Research Labs**
 Sanra Rivett, Ph.D., Associate Global Alliance Director, Global Sciences and Information, **AstraZeneca Pharmaceuticals**
 Steven Tregay, Ph.D., Head of Strategic Alliances Technology, **Novartis**

Keynote Topics & Panel Discussion will include presentations on:

- Alliance Management
- Licensing and Protecting Assets
- Merges and Acquisitions
- The Strategic Role of Partnerships and other Collaborations that Fund the Pipeline

Part II: Early Stage Company Presentations, Executive Coaching & Didactic Panel Critiques • 1-4pm

Three concurrent sessions in: • Diagnostics • Biomarkers • Cancer Therapeutics

Each session will be moderated and critiqued by the part I program experts in Alliances, Licensing, Funding, and Intellectual Property. Selected early stage companies have been reviewed and selected by our scientific and business advisors. (Limited openings still available). Please contact samster@healthtech.com

Roundtable Networking Reception Discussion Groups

"Meet and Greet" executive speakers, panelists and early stage company representatives at moderated roundtable networking discussion groups.

One-to-One Meetings Available all Week Using CHI's Intro-Net

Short Courses (SC)

MORNING

- (SC1) **The Biotech Pharma Partnership - Part I**
 (SC2) **Global Strategies Morning Course**
 (SC3) **Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier**
 see pg. 5 for details
 (SC4) **Microreactors: Integrating Flow Chemistry into Drug Discovery**
 see pg. 5 for details
 (SC5) **Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology Clinical Trial Design**
 see pg. 7 for details
 (SC6) **Preclinical Morning Course**


AFTERNOON

- The Biotech Pharma Partnership - Part II**
 (SC7) **Diagnostics**
 (SC8) **Biomarkers**
 (SC9) **Cancer Therapeutics**
 (SC10) **An Interactive Workshop Including a Business War Game: Does Your Strategy Hurt When I Do This?**
 see pg. 4 for details
 (SC11) **ADMET Case Studies from a Medicinal Chemistry Perspective**
 see pg. 5 for details
 (SC12) **Multi-Plexing and Multi-Probing using Late-PCR and Sloppy Beacons: Applications in Quantitative End-Point Detection**
 see pg. 7 for details
 (SC13) **Microdosing**
 (SC14) **Stem Cell Afternoon Course**

DINNER

- (DC15) **New Ways to Partner in the Personalized Medicine Space**
 see pg. 7 for details

CONFERENCE-AT-A-GLANCE

Tuesday, February 27	Wednesday, February 28	Thursday, March 1	Friday, March 2
Pre-Conference Events	1 Pathway Analysis	1 Pathway Analysis	1 Pathway Analysis
Book Early!*	2 Global Strategies to Reinvent the R&D Business Model- Executive Summit	2 Global Strategies to Reinvent the R&D Business Model- Executive Summit	2 Global Strategies to Reinvent the R&D Business Model- Executive Summit
The first 50 people to register by October 27 will receive a complimentary copy of G. Steven Burrill's Biotech 2006—Life Sciences: A Changing Prescription book and save up to \$350 off your event registration!  	3 Mastering Medicinal Chemistry	3 Mastering Medicinal Chemistry	3 Mastering Medicinal Chemistry
	4 Predictive Preclinical Development	4 Predictive Preclinical Development	4 Predictive Preclinical Development
	5 Molecular Diagnostics	5 Molecular Diagnostics	5 Molecular Diagnostics
	6 Commercial Implications of Stem Cell Research	6 Commercial Implications of Stem Cell Research	6 Commercial Implications of Stem Cell Research
	7 Clinical Trials in India & Asia	7 Clinical Trials in India & Asia	7 Clinical Trials in India & Asia
	8 Trends in Drug Safety	8 Trends in Drug Safety	8 Trends in Drug Safety
	9 Cancer Molecular Markers	9 Cancer Molecular Markers	9 Cancer Molecular Markers

*Promotional Terms:

- 3-day registration + 1 Short Course must be paid in full by October 27, 2006
- A \$395 cancellation fee will be incurred on any cancellation that qualifies for the Book Early Promotion. (\$100 processing fee and \$395 for the cost of the Biotech 2006 - Life Science Book.)
- Biotech 2006 - Life Science Book will be shipped out the week after the October 27th deadline



STREAMLINE Drug and Diagnostic Development Through Pathway Analysis

PLENARY KEYNOTES

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**

Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.

**Partnering and Alliance Trends**

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

PATHWAY DATABASES FOR CANCER RESEARCH

Dr. Nathan Siemers, Director of Bioinformatics, Bristol-Myers Squibb Company

The New Kid on the Block: microRNA Profiling in Cancer from a Bioinformatics Perspective

Yuriy Gusev, Ph.D., Assistant Professor, Department of Surgery, Adjunct Assistant Professor, Institute for Breast Health, Co-Director, Bioinformatics Core facilities, OU Cancer Center, University of Oklahoma

OPEN SOURCE PATHWAY INFORMATION: OPPORTUNITIES AND CHALLENGES**GenMAPP**

Bruce R. Conklin, M.D., Associate Investigator Gladstone Institute of Cardiovascular Disease, Associate Professor of Medicine, University of California, San Francisco

Open Source Pathways Databases: The Reactome Example

Peter G. d'Eustachio, Ph.D., Editor-in-Chief, Reactome, and Associate Professor of Biochemistry and Medicine, Departments of Biochemistry and Medicine, New York University School of Medicine

Pathway Commons - Convenient Access to Pathway Information

Gary Bader, Ph.D., Assistant Professor, Banting and Best Department of Medical Research, University of Toronto

Integrating Genetic, Functional Genomic, and Bioinformatic Data in a Systems Biology Approach to Complex Diseases (Cytoscape)

Allan Kuchinsky, Principal Project Scientist, Molecular Technologies Lab, Agilent Laboratories

RNAi SCREENS FOR TARGET DISCOVERY**RNAi Screens for Target Discovery in Metabolic Disease**

Michael P. Czech, Ph.D., Professor and Chair, Program in Molecular Medicine, University of Massachusetts Medical School

RNAi-Based High-Content Screening for Target Identification

John F. Reidhaar-Olson, Ph.D., Research Leader, Department of Research Informatics, Genetics & Genomics, F. Hoffman-La Roche, Inc.

Screening for Drugable Inflammation Targets

Zaklina Strezoska, Ph.D., Senior Scientist, ALTANA Pharma AG

Robust, Image-Based, RNAi Screens for Oncology Drug Target Identification

Steven A. Haney, Ph.D., Group Leader, Oncology Genomics, Department of Biological Technologies, Wyeth Research

High-Throughput RNAi Screening by Time-Lapse Imaging of Live Human Cells

Jan Ellenberg, Ph.D., Gene Expression & Cell Biology & Biophysics, MitoCheck Project Group, European Molecular Biology Laboratory (invited)

EXPANDING WORLD OF microRNAs: NEW AVENUES FOR DIAGNOSTICS AND THERAPY**miRNAs: Biomarkers for Cancer?**

Aimee Jackson, Ph.D., Research Fellow, Rosetta Inpharmatics, a wholly-owned subsidiary of Merck & Co, Inc.

microRNA as Cancer Biomarkers

David Brown, Ph.D., Head of R&D, Asuragen, Inc.

Genomics of Chronic Lymphocytic Leukemia microRNAs as New Players with Clinical Significance

George Calin, M.D., Ph.D., Research Assistant Professor, Molecular Virology, Immunology & Medical Genetics Department, Comprehensive Cancer Center, Ohio State University

microRNAs in Proliferation and Differentiation

Anindya Dutta, M.D., Ph.D., Byrd Professor of Biochemistry and Molecular Genetics, University of Virginia

USE OF ANIMAL MODELS TO VALIDATE GENE EXPRESSION SIGNATURES**Cholinergic Angiogenesis -- A Novel Endogenous Angiogenic Pathway and its Therapeutic Application to Diseases**

Jenny Wu, Ph.D., Senior Research Scientist, Cardiovascular Medicine, Stanford University

Understanding Anti-Proliferation Mechanism in Animal Models by Genomic Approaches

Chris Huang, Ph.D., Principal Research Scientist, Discovery Research, Centocor Research & Development, Inc.

Organ-Specific Metastasis and Molecular Signatures

Andrew J. Minn, M.D., Ph.D., Assistant Professor, Department of Radiation Oncology, University of Chicago (tentative)

Reversible Type-2 Diabetes Mouse Model Through Doxycycline Regulated ShRNA Expression

Jost Seibler, Ph.D., RNAi Group Leader, Artemis Pharmaceuticals

Understanding Transcriptional Networks with Cap Analysis Gene Expression (CAGE)

Piero Caminci, Ph.D., Genome Science Laboratory, RIKEN

CANCER MOLECULAR MARKERS

(Shared session with Molecular Diagnostics)

Developing Pharmacodiagnosics for Cancer

Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako

Biomarkers and Development of Targeted Therapies

Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline

Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective

Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor

Driving Down Development Costs by Using Biomarkers

Karol Sikora, M.A., MBBCh, Ph.D., FRCP, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC

Detection of Cancer through Circulating DNA

Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)



Fifth Annual R&D Executive Summit

GLOBAL STRATEGIES TO REINVENT THE R&D BUSINESS MODEL

February 28-March 2, 2007

Sponsored By:



INTEGRATE Licensing, Alliance management, International Collaborations and Lean Thinking Into Your Organization

PRE-CONFERENCE SHORT COURSES (SC)

(SC2) Morning Course

(SC10) An Interactive Workshop Including a Business War Game: Does Your Strategy Hurt When I Do This?

Mark Chussil, Founder and CEO, Advanced Competitive Strategies, Inc.

PLENARY KEYNOTE



Partnering and Alliance Trends

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

NEW APPROACHES, NEW PARADIGMS AND NEW BUSINESS MODELS FOR STRUCTURING R&D FOR LONG-TERM VIABILITY

Chairperson's Remarks

Andrew L. Hopkins, Ph.D., Associate Research Fellow, Knowledge Discovery, Pfizer Global R&D

Complementing Internal R&D with External Innovation and Integrated Partnership Strategies: Driving Value through Proactive Alliance Management

Lorenz Ng, M.D., Ph.D., Vice President, Research & Alliance & Business Development, Asia Pacific, Eli Lilly & Co. (Asia)

Pharmacogenetics Discovery and Development for New Medicines

Dan Burns, Ph.D., Senior Vice President, Therapeutic Matrix, Compliance and Pharmacovigilance, GlaxoSmithKline

Is Drug Development, as We Know it Today, Going the Way of the Dinosaurs?

Eliot R. Forster, Ph.D., Vice President, Development, Pfizer Inc.

PARTNERING AND COLLABORATION STRATEGIES FOR PHARMA AND BIOTECH

Chairperson's Remarks

James F. Resch, Ph.D., Director Strategic Intelligence, Global Discovery Strategy Portfolio & Alliances, AstraZeneca Pharmaceuticals, Inc.

Collaborative Mechanisms - Innovative Models and Approaches for the Life Sciences

Christina Sampogna, Directorate for Science, Technology and Industry, Organization for Economic Cooperation and Development (OECD)

Case Study

Building Strong Partnerships with Academia and Biopharma Companies in China

Mao Mao, M.D., Ph.D., Associate Director/China Project Liaison, Oncology Clinical Research, Merck Research Laboratories (invited)

Outside Funding of Development Programs without Transfer of IP or Loss of Control

Creative Thinking about and Models for Financing Large, High-Risk, Long-Term Investments that Could Lead To Biomedical Breakthroughs: FasterCures' Acceleration Agenda

Greg Simon, President, FasterCures - Center for Accelerating Medical Solutions

INTERNATIONAL COLLABORATIONS & OUTSOURCING: INTEGRATING EXTERNAL AND INTERNAL RESOURCES

Chairperson's Remarks

Steven M. Hutchins, Senior Director, Global Basic and Preclinical Sourcing, Merck & Co.

Outsourcing of R&D and Manufacturing: Regulatory Oversights on International Collaborations

Subhash Dhawan, Ph.D., Senior Investigator and Chief, Immunopathogenesis Section, US Food and Drug Administration (CDER)

Pharma Innovation and Clinical Development in China

James Cai, Ph.D., Vice President, Research and Development, AstraZeneca China

IMPROVING DISCOVERY AND DEVELOPMENT PRODUCTIVITY BY GOING GLOBAL: LEVERAGING EMERGING GLOBAL MARKETS

Leveraging Capabilities in China, India and other Emerging Countries: Successfully Assessing Feasibility, Modeling Options, and Evaluating Partners for Emerging Capabilities

Eugene Williams, CEO, Cambridge Healthtech Associates

Eric Meyers, General Manager, Global Developer, Cambridge Healthtech Associates

Panel Discussion

Strategies for Successful Outsourcing of Preclinical Development in Asia

Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.

OVERCOMING IP, QUALITY, INFRASTRUCTURE, COMMUNICATION AND CONTROL ISSUES IN EMERGING REGIONS

Chairperson's Remarks

Balu Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers Squibb Co.

Strategies to Minimize IP Risk and Maximize Protection in the Rapidly Developing Legal Landscape

Capitalizing on Asia's Unique Characteristics to Improve R&D's Productivity

Eric Morfin, Director, Project Management Office, Novartis Vaccines and Diagnostics

Building a High-Performing, Multinational R&D Organization in China

Case Study

Opportunities and Pitfalls of Establishing an R&D Service Organization in India

Antal K. Hajos, Ph.D., Managing Director, ALTANA Pharma Priv. Ltd.

Panel Discussion

The Impacts of and Strategies for Outsourcing of Medicinal Chemistry

M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.

Frederik Deroose, Ph.D., Head, External Chemistry & Outsourcing Services, J&J PRD

STRATEGIES FOR LOWERING ATTRITION, IMPACTING SUCCESS AT PROOF-OF-CONCEPT & IMPROVING PROCESSES

Chairpersons' Remarks

Mark I. Cockett, Ph.D., Vice President, Applied Genomics, Bristol-Myers Squibb Co.

R&D Productivity Levers - Are all Productivity Improvements Equal?

Aaron Schacht, Executive Director, R&D Strategy, Portfolio & Project Management, Eli Lilly

Is Drug Discovery Ready for Lean Thinking?

Edward W. Petrillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC

Case Studies

Peptide Therapies and Research Program Planning: Marrying Research Innovation with Project, Portfolio and Resource Management to Deliver Significant New Peptide-Based Therapeutics

James Paterniti, Ph.D., Senior Director, Research Program Planning, Amylin Pharmaceuticals,

Learning from Non-Pharma Industries: Understanding Others' Mastery of Processes

How Wyeth is Transforming R&D: The Learn and Confirm Model of Clinical Development

Matthew Bell, Ph.D., MA, Senior Director, Learn and Confirm Implementation Office, Wyeth

Topic to Be Announced

Christine Cioffe, Vice President, R&D Portfolio Management, Merck & Co.

SUCCEEDING IN A FUTURE OF HIGH ATTRITION BY EFFECTIVELY MANAGING R&D PROJECTS AND PROCESSES

Chairperson's Remarks

Edward W. Petrillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC

Case Study

Life Science Industries - Managing a Turbulent Future

Professor Joyce Tait, CBE, FRSE, Ph.D., Director, ESRC Innogen Centre (Centre for Social and Economic Research on Innovation in Genomics), University of Edinburgh

R&D Performance Measurements: More than Choosing a Set of Metrics

Shama Kajiji, Ph.D., MBA, Director, WorldWide Project Management, Pfizer Inc.

Panel Discussion

Effectively Managing R&D Projects and Processes: Successes and Failures

MASTERING MEDICINAL CHEMISTRY

Delivering Pre-Development Compounds in Multiple Therapeutic Areas

February 28-March 2, 2007

Corporate Sponsor:



LEARN Strategies to Tackle Difficult Targets in Multiple Therapeutic Areas

PRE-CONFERENCE SHORT COURSES (SC)

February 27, 2007

(SC3) Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier

- Novel Targets Identification and Validation
- Novel Delivery Strategies
- Dealing with the Liability of CNS Drug Side-effects
- Crossing the Blood-Brain Barrier - BBB Penetration
- Pharmacokinetics and Drug Metabolism

(SC4) Microreactors: Integrating Flow Chemistry into Drug Discovery

- The Challenges of Switching from Batch to Flow Chemistry
- Scaling Up and Improving Safety
- Reproducibility
- Performing Reactions with Different Solvents
- Handling Precipitates and Solids – Is there a “Solution” in Sight?
- Are Microreactors Ready for General Use in Drug Discovery Laboratories?

(SC11) ADMET Case Studies from a Medicinal Chemistry Perspective

- Understanding How to Evaluate ADME Data
- Diagnostic PK Assays
- QSAR for Medicinal Chemists
- Case Studies from Real Projects

PLENARY KEYNOTE**Partnering and Alliance Trends**

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

EXECUTIVE OVERVIEW - FUTURE DIRECTIONS FOR MEDICINAL CHEMISTRY**Featured Speaker****Lead Generation for Difficult Targets**

Hanno Wild, Head of Discovery Europe, Bayer HealthCare AG

Over the last ten years Bayer HealthCare has built up its compound library to almost 2 million single compounds. In parallel, ultra high-throughput screening in the 1536 format was established as the standard technique for lead finding. The success of this approach could be demonstrated by the discovery of novel lead structures for targets which were difficult to approach so far: Non-basic inhibitors of Factor Xa, competitive inhibitors of human neutrophil elastase, non-nucleosidic adenosine agonists.

THE IMPACT OF OUTSOURCING AND OFF-SHORING ON MEDICINAL CHEMISTRY

- Maintaining corporate growth while increasing project capacity
- The impact of library and hit-to-lead outsourcing on medicinal chemistry
- Can current outsourcing companies provide adequate medicinal chemistry?
- Retraining medicinal chemists in more creative and higher skilled aspects of chemistry

Frederik Deroose, Ph.D., Head of External Chemistry & Outsourcing Services, Johnson & Johnson Pharmaceutical Research & Development

M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.

DOMAIN DRIVEN MEDICINAL CHEMISTRY - DIFFERENT APPROACHES FOR CNS, CANCER, METABOLIC AND CHRONIC DISEASES**Metabolic Disorders****Selective Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: The Discovery of Januvia™ (Sitagliptin)**

Scott D. Edmondson, Ph.D., Senior Research Fellow, Merck Research Laboratories

Metabolic Disease Target Validations using Small Molecule Agents: Compare and Contrast with Genetic Depletion Models

Gang Liu, Ph.D., Senior Group Leader, Associate Research Fellow, GPRD-Metabolic Disease Research, Abbott Laboratories

PTP1B Inhibitors: New Leads for a Challenging Drug Target via Structure-based Drug Design Methods

Andrew Combs, Ph.D., Senior Director, Chemistry, Incyte Corporation

Rational Design of Potent, Selective, Efficacious and Safe DPP4 Inhibitors as a Treatment of Type 2 Diabetes

Zhong-hua Pei, Ph.D., Research Investigator, Metabolic Disease Research Global Pharmaceutical Research & Development, Abbott Laboratories

Is Malonyl-coa Decarboxylase a Viable Therapeutic Target?

Jie-Fei Cheng, Ph.D., Director, Chemistry, Tanabe Research Laboratories USA

Inflammation**The Identification of Selective Lck Inhibitors for the Treatment of Solid Organ Transplant Rejection**

Gavin Hirst, Ph.D., Associate Director, Medicinal Chemistry, Abbott Bioresearch Center

Oncology**Progesterone Receptor Antagonists - A Successfully Completed Lead Optimization Program**

Wolfgang Schwede, Ph.D., Senior Scientist, Medicinal Chemistry, Schering AG

The Discovery of SKI-606: A Dual Inhibitor of Src and Abl Kinases in Clinical Development for the Treatment of Cancer


Diane H. Boschelli, Ph.D., Principal Research Scientist, Chemical and Screening Sciences, Wyeth Research

From the Insoluble Dye Indirubin Towards Highly Active, Soluble CDK2-Inhibitors

Rolf Jautelat, Ph.D., Principal Scientist, Medicinal Chemistry, Schering AG

CNS**New Pharmaceuticals from Neurotransmitters: Drugs for the Brain from the Brain**

Robin Polt, Ph.D., Professor, Chemistry/Pharmacology, The University of Arizona



"This was one of the best conferences that I have been to in recent years. It combined intellectual stimulation with an exposure to the latest advances in medicinal chemistry. In addition it offered a unique opportunity to meet and talk with leaders in the field, as well as with colleagues involved in many diverse aspects of drug discovery and development."

Anu Mahadevan, Ph.D., Vice President, Organix, Inc. (2006 Alumna)

PREDICTIVE PRECLINICAL DEVELOPMENT

Safety Biomarkers, Microdosing, and Selecting First Dose in Humans

February 28-March 2, 2007

Sponsored By:

iAdvantage

OPTIMIZE candidate progression from DISCOVERY to EARLY CLINICAL evaluation

Scientific Advisory Board

Joy Cavagnaro, Ph.D., DABT, RAC, President, Access BIO

Rakesh Dixit, Ph.D., DABT, Senior Director & Global Head, Toxicology Department, MedImmune Inc.

David S. Lester, Ph.D., New York Site Head, WorldWide Clinical Technology, Pfizer Inc.

Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.

PLENARY KEYNOTES**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**

Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.

**Partnering and Alliance Trends**

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

CANCER BIOMARKER DEVELOPMENT**Keynote****FDA Perspective on Cancer Biomarker Development: What are the Challenges in Bringing These to Market?**

Larry G. Kessler, Sc.D., Director, Office of Science & Engineering Labs, FDA

SELECTING FIRST DOSE IN HUMANS**New Emerging Safety Biomarkers: Utility in Preclinical and Clinical Safety Assessment**

Rakesh Dixit, Ph.D., DABT, Senior Director and Head, Toxicology Department, Translational Sciences, MedImmune Inc.

Estimating First in Human Doses for Biologics: Factoring in Safety, Pharmacology and Proposed Therapeutic Dose

Jennifer E. Visich, Ph.D., Director, Pharmacokinetics and Pharmacodynamics, ZymoGenetics Inc.

The Use of Preclinical Animal Studies to Assist in Dosage Selection for Phase 1 Human Clinical Trials

Stanley Roberts, Ph.D., Vice President, Preclinical Development, CovX Research, LLC

Selecting Relevant Non-Clinical Biomarkers to Establish Human First Dose Levels

Christopher Horvath, D.V.M., M.S., Senior Director, Toxicology, Archemix Corp.

Implementing Microdosing or Phase 0 Trials

Richa Chandra, M.D., M.B.B.S., M.B.A., Senior Director, Clinical R&D, Translational Medicine Lead, Infectious Diseases, Pfizer Research & Development

OUTSOURCING PRECLINICAL DEVELOPMENT IN ASIA**Outsourcing Preclinical ADMET to China: Opportunities and Challenges**

Chun-Lin Chen Ph.D., President and Chief Executive Officer, Medicilon

China in a Global Drug Development Landscape

Jonathan Wang, Ph.D., General Manager, Burrill Greater China Group (BGCG), Burrill & Company

Outsourcing Pharmaceutical Sciences

Ming Guo, Ph.D., Vice President, Pharmaceutical Sciences & Manufacturing, Ascenta Therapeutics, Inc.

Panel Discussion**Strategies for Successful Outsourcing of Preclinical Development in Asia**

Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.

HOW MANY NEW BIOMARKERS DO WE NEED?

Cost-Benefit Analysis of New Biomarkers

Barriers on the Road to New Protein Biomarkers: Confronting the Biomarker Validation Bottleneck

Leigh Anderson, Ph.D., Founder & Chief Executive Officer, Plasma Proteome Institute

Biomarkers, Biological Diversity, and Decision Making: What to Measure, What it Means, and Why it has Value

Thomas Paterson, Co-founder, Senior Vice President, Entelos Inc.

StaRT-PCR Measurement of Anti-Inflammatory Gene Transcript Abundance in Whole Blood Provides Accurate Biomarkers for RA Individuals

James C. Willey, M.D., Founder & Chief Science & Medical Consultant, Gene Express Inc. and Professor of Medicine and Pathology, George Isaac Professor for Cancer Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Toledo

Too Few Qualified Biomarkers for High Value Needs

Howard Schulman, Ph.D., Vice President, PPD Biomarker Discovery Sciences, LLC, and Consulting Professor of Neurobiology and of Molecular Pharmacology, Stanford University

Panel Discussion**Developing a Business Model for Risk Management of Innovative Technologies**

- How much do things cost? Time and money.
- What is the added value?

CORRELATING IMAGING WITH CLINICAL EXPERIENCE**Keynotes**

Richard Hargreaves, Ph.D., Vice President, Imaging, Merck & Co., Inc. (invited)

A. Gregory Sorensen, M.D., Director, Center for Biomarkers in Imaging, Associate Director, Martinos Center for Biomedical Imaging, and Associate Professor of Radiology, Harvard Medical School and Massachusetts General Hospital

Image-Based Biomarker Quantifications

Edward Ashton, Ph.D., Chief Scientific Officer, VirtualScopics, Inc.

Affibody Molecules, a Novel Class of Affinity Ligands for Molecular Imaging of HER2-Positive Breast Cancer Preclinical and Clinical Applications

Joachim Feldwisch, Ph.D., Project Manager, Research, Affibody AB

Imaging Biomarkers for Cognitive Enhancing and Psychotropic Therapies

Cameron Carter, M.D., Imaging Research Center, U.C. Davis

"Again, the organizers of the Molecular Medicine Tri-Conference have compiled a group of outstanding speakers/scientists in the area of preclinical/clinical drug safety to address a variety of contemporary topics/issues of high interest in the fields of pre-clinical toxicology and drug development."

George M., Vice President, Drug Safety & Disposition, Cephalon, Inc. (2006 Alumnus)

MOLECULAR DIAGNOSTICS:

Driving Quality of Care in Medicine

February 28-March 2, 2007

DISCOVER, CHOOSE, VALIDATE, and INTRODUCE biomarker products

PRE-CONFERENCE SHORT COURSES

Tuesday, February 27, 2007

(SC5) Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology Clinical Trial Design

Chairperson: Leon Terstappen, M.D., Ph.D., Vice President of R&D, Immunicon

(SC12) Multi-Plexing and Multi-Probing using Late-PCR and Sloppy Beacons: Applications in Quantitative End-Point Detection

Lawrence Wagh, Ph.D., Associate Professor, Department of Biology, Brandeis University and Fred Kramer, Ph.D., Professor, Department of Microbiology, Public Health Research Institute

(DC15) New Ways to Partner in the Personalized Medicine Space

Moderator: Peter S. Miller, Chief Operating Officer, Genomic Healthcare Strategies

Panelists: Michael S. Paul, Ph.D., President & Chief Executive Officer, LineaGen Partners, Inc. Annie Brooking, Chief Executive Officer, Astron Clinica

PLENARY KEYNOTES



Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints

Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.



Partnering and Alliance Trends

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

Keynote



FDA Perspective on Cancer Biomarker Development: What are the Challenges in Bringing These to Market?

Larry G. Kessler, Sc.D., Director, Office of Science & Engineering Labs, FDA

Interpretation of Data

Arthur L. Holden, M.B.A., Senior Vice President, Corporate Development, Illumina Inc.; Chairman, Pharmaceutical Biomedical Research Consortium, Ltd.

Special Nature of Genetic Testing

Paul Billings, M.D., Ph.D., Senior Vice President, Corporate Development and Strategy, LabCorp

CHANGING STRATEGIES AROUND BIOMARKER PARTNERSHIPS

State of the Industry

Harry Glorikian, Managing Partner, Strategic Advisory, TSG Partners

Key Intervention Points for Global Health Diagnostics, the Impact of the Introduction of Diagnostics

Carol Dahl, Ph.D., Director for Global Health Technologies, Bill & Melinda Gates Foundation

Panel Discussion

From Concept to Implementation - Addressing Global Health Needs

CASE HISTORIES IN SERUM-BASED MARKERS: THE STATE-OF-THE-ART FOR MOLECULAR DIAGNOSTICS

Diagnosing Prion Diseases: Needs, Challenges, and Hopes

Claudio Soto, Ph.D., Distinguished Professor and Director Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, and Chief Scientific Officer and Founder, Amprion Inc.

Detection of EGFR in Blood May Predict Iressa and Tarceva Response in Lung Cancer

Stephen Little, Ph.D., Chief Executive Officer, DxS Ltd.

Serum HER-2/neu as a Biomarker for HER-2 Positive Metastatic Breast Cancer (MBC)

Walter P. Carney, Ph.D., Head, Oncogene Science, Bayer HealthCare

IMPROVEMENTS IN OVARIAN CANCER SCREENING

Translating Genomic Data into Multi-Analyte Serum Biomarkers for Early Detection of Ovarian Cancer

Garret M. Hampton, Ph.D., Senior Director, Biochemistry & Biomarker Development, Celgene

Proteomic Biomarkers for Ovarian Cancer: Discovery, Validation and Translation

Daniel W. Chan, Ph.D., DABCC, FACB, Professor of Pathology, Oncology, Radiology & Urology; Director of Clinical Chemistry Division, Department of Pathology; Director, Center for Biomarker Discovery, Johns Hopkins Medical Institutions

Serum Multimarker Assay for Early Detection of Ovarian Cancer

Anna Lokshin, Ph.D., Assistant Professor of Medicine, University of Pittsburgh

Gene Expression-Driven Cancer Diagnostics

Yixin Wang, Ph.D., Group Director, Discovery Research and Pharma Biomarker Support, Veridex, Johnson & Johnson

Panel Discussion

Turning Discoveries into Clinical Products

Executive Strategy Panels

Diagnostic Wish List

Moderator: Harry Glorikian, Managing Partner, Strategic Advisory, TSG Partners

Panelist: Ronald M. Krauss, M.D., Senior Scientist and Director, Atherosclerosis Research, Children's Hospital Oakland Research Institute; Guest Senior Scientist, Department of Genome Sciences, Lawrence Berkeley National Laboratory; and Adjunct Professor, Department of Nutritional Sciences, University of California, Berkeley

Personalized Medicine Coalition's Landscape Analysis

Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition

Commercial Opportunities in Molecular Diagnostics

Moderator: Keith F. Batchelder, M.D., Chief Executive Officer and Founder, Genomic Healthcare Strategies

Panelists: Carol Reed, M.D., Senior Vice President and Chief Medical Officer, Clinical Data, Inc. (tentative)

Stéphane Bancel, Executive Vice President, bioMérieux sa

Jean-Luc Vanderheyden, Ph.D., Molecular Imaging Leader, GE Healthcare (invited)

UNDERSTANDING EPIGENETICS AND METHYLATION PATTERNS OF DISEASE

Epigenetics of Cancer Etiology

Andrew P. Feinberg, M.D., M.P.H., Professor, Molecular Medicine, Department of Medicine, Department of Oncology, Department of Molecular Biology & Genetics, Johns Hopkins University

QM-MSP-based Detection of Methylated Genes for Early Detection of Breast Cancer

Sara Sukumar, Ph.D., Professor of Oncology and Pathology, Johns Hopkins University

Biomarker Discovery: Mining the Cancer Epigenome

Jared Ordway, Ph.D., Senior Scientist and Program Leader, Discovery, Orion Genomics LLC

Panel Discussion

Steps Needed to Translate DNA Methylation Biomarkers to Clinical Chemistry

CANCER MOLECULAR MARKERS

(Shared session with Pathway Analysis)

Developing Pharmacodiagnosics for Cancer

Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako

Biomarkers and Development of Targeted Therapies

Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline

Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective

Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor

Driving Down Development Costs by Using Biomarkers

Karol Sikora, M.A., MBBCh, Ph.D., FRCP, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC

Detection of Cancer through Circulating DNA

Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)

COMMERCIAL IMPLICATIONS OF STEM CELL RESEARCH

February 28-March 2, 2007

BRIDGING Biology and Business to SUPPORT the Science

Supporting the science can only be achieved once scientists have the power to manipulate cells by a thorough understanding of how to "reprogram" stem cell behavior. However, the vision to launch a medical revolution takes commitment and cash. Cambridge Healthtech Institute's Second Annual Commercial Implications of Stem Cell Research continues the advancement of stem cell research by addressing the current reality and currency required to fulfill their power, potential, promise, and profitability.

Scientific Advisory Committee

Joe Bielitzki, DVM, University of Central Florida
 Lee Buckler, LLB, Progenitor Cell Therapy
 Robert Deans, Athersys, Inc.
 Robert Harman, DVM, Vet-Stem, Inc.
 Rosemarie Hunziker, Ph.D., NIH NIDCR
 Mark Levenstein, Ph.D., WiCell Research Institute
 Deepak Srivastava, M.D., University of California-San Francisco
 Evan Snyder, M.D., Ph.D., The Burnham Institute

PLENARY KEYNOTES



Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints

Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.



Partnering and Alliance Trends

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

KICK-OFF KEYNOTE

Selling the Stem Cell Dream

Irving Weissman, M.D., Ph.D., Director, Institute of Stem Cell Biology and Regenerative Medicine and Professor of Pathology and Developmental Biology, Stanford University (invited)

INTERACTIVE PANEL DISCUSSIONS

Topics to be discussed:

- Basic Biology
- Scale-up
- Regulation
- Funding
- Patient Advocacy Groups
- Public Perception
- Legal Issues

BRIDGING BIOLOGY AND BUSINESS

Human Embryonic Stem Cells - Promise and Progress

Thomas B. Okarma, M.D., Ph.D., President and CEO, Geron Corporation

The Paths around Stem Cell Intellectual Property

Kenneth Taymor, A.B., Attorney, MBV Law LLP; Lecturer, Stanford Law School (tentative)

Stem Cells: The Facts Not the Debate

Arnold Kriegstein, M.D., Ph.D., Director, Developmental and Stem Cell Biology and Professor, Neurology, University of California, San Francisco (invited)

STEM CELLS AND REGENERATIVE HEALING

Enhancing Stem Cell Functionality in Aged Tissues

Thomas A. Rando, M.D., Ph.D., Associate Professor, Department of Neurology and Neurological Sciences, Stanford University School of Medicine

Potential of Stem-Cell-Based Therapies for Heart Disease

Deepak Srivastava, M.D., Professor and Director Gladstone Institute of Cardiovascular Disease, Wilma and Adeline Pirag Distinguished Chair, Department of Pediatrics, University of California San Francisco

Molecular Imaging of Stem Cell Therapy

Joseph C. Wu, M.D., Ph.D., Instructor, Cardiovascular Medicine, Stanford University School of Medicine

"The continuity of discussion from process to product was both eye opening and exciting. It gives the CHI conference a distinct signature that highlights it as a premier conference for basic and applied scientists alike."

Mark L., Research Scientist, WiCell Research (2006 Alumnus)

Save the Date!

Thursday, March 1, 5:30 pm - 7:00 pm

"Wines of California & Dinner Reception"

Join us for a wine tasting dinner reception hosted by CHI. We will offer you the opportunity to network while experiencing California food and wine. The visiting wine makers will be pouring featured wines paired at tasting stations. Learn and discern with experts on hand.

Renaissance Parc 55 Hotel located in Union Square, a few blocks from the Moscone. All are invited to enjoy the reception after Thursday's sessions.



CHI's Intro-Net: Networking at Its Best! Maximize Your Experience Onsite at the Molecular Medicine Tri-Conference!

Cambridge Healthtech Institute's



The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is only available to registered session attendees of this event.

For more information, visit: www.Tri-Conference.com/intronet.asp

"The Intro-Net was an excellent networking tool for me, and I made several direct meeting connections that have turned into real potential strategic relationships."
 Eric B. D., Chairman/CEO, Genetic Assays, Inc.

TRACK :**7***Inaugural***CLINICAL TRIALS IN INDIA & ASIA****February 28-March 2, 2007****NEW!****REDUCE costs, GAIN access to large patient populations and a GROWING consumer market**

Globalization of clinical trials is a growing trend driven by the need to reduce costs, gain access to large patient populations, and a growing consumer market. Making clinical trials more efficient is going to be key for success, and the leaders in this area need to be aware of how this rapidly changing environment can affect their business. This conference will explore strategies for implementing parallel trial design for US and overseas, that involves integrating data from disparate sites. The barriers to managing clinical trial sites overseas for this highly regulated and controlled area will be carefully weighed.

SESSIONS INCLUDE:

- Patient Registration and Recruitment
- Regulatory Concerns
- IP Protection
- Protecting Patient Safety
- Ensuring Ethical Compliance
- Managing Global Sites
- Access to Trained Foreign Clinical Investigators
- Approved Facilities, Monitoring Practices
- Handling Data from Disparate Sources
- Drug Registration

TRACK :**8***Third Annual***TRENDS IN DRUG SAFETY****February 28-March 2, 2007****FIRST! IMPROVING drug efficacy to OVERCOME safety issues****STRATEGIES FOR IMPROVING DRUG SAFETY**

- Manage risk proactively to lower candidate attrition
- Decrease failure with pharmacodynamic biomarkers
- Feed information from clinical trials into discovery phase
- Quantitate benefit-risk management
- Review case study in drug-redirecting
- Gain insights from imaging biomarkers
- Select compounds in man
- Choose the right animal model
- Predict human sensitivity
- Develop biomarker assays

SESSIONS INCLUDE:

- Cancer Biomarker Development
- Selecting First Dose in Humans
- How Many New Biomarkers do we Need? A Cost-Benefit Analysis of New Biomarkers
- Correlating Imaging With Clinical Experience
- Exploratory IND's and Microdosing

"Trends in drug safety is an excellent forum for scientists and clinicians from academia and industry to learn about the needs, advances and opportunities occurring on the other side of the fence."

Eric A., Molecular Imaging Scientist, GE Healthcare (2006 Alumnus)

TRACK :**9***Inaugural***CANCER MOLECULAR MARKERS****February 28-March 2, 2007****NEW!****SESSIONS INCLUDE:**

- Cancer Biomarker Development
- Case Histories in Serum-Based Markers

- Understanding Epigenetics and Methylation Patterns of Disease
- Expanding World of microRNAs: New Avenues for Diagnostics and Therapy
- Improvements in Ovarian Cancer Screening
- Cancer Molecular Markers

Present a Poster and Save \$50!

- Your poster will be available to over 2,300 delegates
- You'll automatically be entered into our Poster Competition, where two winners will receive \$500
- Receive \$50 off your registration fee
- Your poster abstract will be published on the event ad
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes
- **Plus!!** All posters will be included in the Molecular Medicine Tri-Conference Poster Abstract Book



Your abstract must be submitted, accepted, and registration paid in full by January 23, 2007.

EXHIBIT AND SPONSOR INFORMATION

Molecular Medicine Tri-Conference is the predominant pharmaceutical/biotechnology event on the West Coast delivering an International audience of 2,300 decision-makers.
60% of last year's delegates held Director level titles and higher!

Sponsorship Information

Sponsorship participation provides your company the opportunity to promote your company's solutions to this targeted and hard-to-reach market. Custom designed sponsorship programs enable you to competitively position your company as a leader in the biotech and pharma industries, and collect quality leads in formal and informal settings. CHI sales managers work with you to shape a sponsorship program that suits your companies sales objectives and budget.

Sponsorship Opportunities:

- **Keynote Introductions & Chair Drops**
- **Podium Presentation Workshops**

Whether you are ready to present an exciting new technology, preparing for a new product launch or need feedback on a specific idea, this conference offers the perfect platform for you to present in front of your target audience. Workshops are embedded within the main conference program, allowing you to present for 30 minutes on a topic directed to your target audience.

- **Luncheon and Breakfast Workshops**

CHI will market your workshop and will continue to promote attendance on-site by providing a gift to be raffled. Business cards are also collected on your behalf for your post-workshop follow-up campaign.

- **Focus Group**

CHI will deliver 7-10 pre-qualified participants and provide the venue for your market research focus group.

- **Invitation-Only Hospitality Suite Reception or**
- **Invitation-Only Dinner**

Offers you the ability to hand-pick delegates to attend your function.

"Vineyards of California" Dinner Reception

A Premier Sponsorship!



A wine tasting and dinner reception after Thursday's sessions at the Renaissance Parc 55 Hotel located in Union Square, a few blocks from the Moscone. An excellent opportunity to sponsor this very successful networking event! Last year over 400 delegates attended this fun and lively event.



Exhibit Information

Exhibit Dates: February 28 – March 1, 2007

**Reserve space by October 30th
to receive a discounted rate!**

Companies exhibiting will experience a highly qualified audience. Nearly 60% of attendees in 2006 held Director level titles and higher. 47% are from biotech companies, 26% from pharma! 77% of the audience represented the USA, 13% from Europe and 6% from Asia.

Please visit the web site for an updated floor plan and the current 2007 exhibitors and a full listing of exhibit benefits, or call David Karp at 781-972-5483, or Carol Dinerstein at 781-972-5471 for details.

CHI Supports Your Participation!

CHI's Cooperative Marketing Program

CHI is pleased to help market to your prospect list at a shared cost. We will offer your prospects a discounted rate to attend the conference on your behalf via mailing or email. CHI's Marketing Manager will customize a specific message to your target audience.

For sponsorship and exhibit opportunities please contact:

Carol Dinerstein, 781-972-5471, dinerstein@healthtech.com

David Karp, 781-972-5483, dkarp@healthtech.com

PRODUCT LAUNCH?

CHI will help market your product launch!

As an exhibitor announcing a new product, your launch news will be included in:

- One Joint ad in a key industry publication
- One Product Update email campaign to over 100,000 prospects and pre-registered delegates
- Product description in a press release announcing product launches at the event
- Corporate listing within an ad in the Program & Event Guide (distributed on-site)

Exhibit Hours

**Wednesday,
February 28:**

9:40am - 5:00pm

Thursday, March 1:

10:00am - 3:45pm

2007

Exhibitors & Sponsors

Analytical Biological Svcs.

AnalytiCon Discovery

Applied Biosystems

Biosearch Technologies

Biotope

Carna Biosciences

ChemBridge

ChemDiv

CHI Marketing Services

Dharmacon

DxS Ltd.

Exagen Diagnostics

FEI Company

GE Healthcare

GeneGo

Gentris Corporation

iAdvantage Software

Ingenuity Systems

INVITROGEN

Jubilant Biosys

Kalxysyn Inc.

Key Organics Ltd.

Kodak Molecular Imaging

Nanosyn Inc.

NuGEN Inc.

Oxonica Inc.

Pall Life Sciences

Peakdale Molecular

PharmaCore Inc.

PreClinoMics Inc.

Progenitor Cell Therapy

QIAGEN Inc.

Reaction Biology

Seradyn


SiDMap

Siemens Medical Solutions

Source MDx


Zygon

Venue, Hotel and Travel Information



Conference & Exhibit Venue:

The Moscone North
Convention Center
747 Howard Street
San Francisco, CA 94103



Headquarter Hotel:

Renaissance Parc 55 Hotel
55 Cyril Magnin Street
San Francisco, CA 94102
Special Group Rate: \$189
Reservation Cut Off Date:
February 6, 2007

Travel Information



"Only in San Francisco"

Take a family vacation to discover San Francisco. Enjoy all the "City by the Bay" has to offer. Take a cruise over to Alcatraz, walk along Fisherman's Wharf, have dim sum in Chinatown, stroll through historic North Beach. Find out more about these and everything else San Francisco has to offer at www.onlyinsanfrancisco.com

Flight Discount:

Discount fares are available on United, United Express, United code share flights (UA*) operated by US Airways, and US Airways Express. You can receive up to a 15% discount off if you or your travel agent calls United's toll-free number 1-800-521-4041. Reference Meeting ID Number 579YS.

Car Rental Discount:

Special discount rentals have been established with AVIS for this conference. You can reserve online at www.tri-conference.com/hotel.asp or call AVIS directly at 800-331-1600. You must reference your Avis Worldwide Discount (AWD) Number J868190.

To make reservations online go to
www.Tri-Conference.com/hotel.asp

or call

1-800-697-3103 or 415-392-8000 and

ask for the

Molecular Medicine Tri-Conference

group rate.

Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space and-rate availability basis. Rooms are limited, so please book early.

A warmly appointed luxury hotel, situated in the heart of San Francisco, the hotel is 2 blocks from the renowned Union Square shopping area and theatre district; within walking distance of the San Francisco Museum of Modern Art and the Yerba Buena Gardens; near the Moscone Convention Center and financial district. You're just minutes from the East Bay, with convenient access to BART (Bay Area Rapid Transit), and the cable car is only a half-block away.

Sponsoring Publications:

Asia Monitor

**American
Pharmaceutical
Outsourcing**
The Journal of Pharmaceutical & Biopharmaceutical Contract Services

**American
Pharmaceutical
Review**

BioDrugs

**BUSINESS
MONITOR
international**

Cancer Drug News

CHEMICAL BIOLOGY & DRUG DESIGN

DRUG DISCOVERY & DEVELOPMENT

Drug Development and
Industrial Pharmacy

DRUG DISCOVERY NEWS
THE NEWS AND BUSINESS OF DISCOVERY SCIENCE

Drug Safety

Emerging Europe Monitor

espicom
Diagnostics Focus

**European
Biotechnology
Science & Industry
News**

GP

**Journal of
Business
Strategy**

**the Journal of
Molecular
Diagnostics**

Inpharma
weekly

Molecular Diagnosis & Therapy

Lab Manager
Where Science and Management Meet

NGP
NextGen Pharmaceutical
www.ngpharma.com

Pharma Company Insight
The latest news on pharmaceutical companies and their products

SYNTHESIS
Journal of Synthetic Organic Chemistry

SYNLETT
Synthesis and Rapid Communications in Synthetic Organic Chemistry

SYNFACTS
Synthetic Factories: Synthesis, Technology, and Business

**THOMSON
CENTERWATCH**

WPM
World Pharmaceutical Markets

Web Partners:

bio.com
I do run this Net

biolexis
for a better deal
<http://www.biolexis.com>

BIOSCREENING.COM
DRUG DISCOVERY PORTAL

BioSpace

**Cell Therapy
NEWS**

CanBiotech
Biotechnology Portal
& B2B Marketplace

selectscience.net
The Scientists' Choice

hum-molgen.org
central gateway to
HUMAN MOLECULAR GENETICS

www.PharmCast.com
Pharmaceutical Internet

Supporting Organizations:

BAYBIO

bio center
SAN JOSE

ALUMNI DISCOUNT

Receive 25% Off Your Registration!

Cambridge Healthtech Institute (CHI) appreciates your past participation at the Molecular Medicine Tri-Conference. Through loyalty like yours, CHI has been able to build this event into a must attend for senior level decision-makers. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 25% off the registration rate. Just check off the box marked Alumni Discount on the registration form to receive the discount!

Please note: Our records must indicate you were an attendee of the Tri-Conference event in the past in order to qualify.

YES! Register me for CHI's Molecular Medicine Tri-Conference

MMTC P

Conference: February 27-March 2, 2007 • Exhibits: February 28-March 1, 2007
Moscone North Convention Center • San Francisco, CA

To Register

Web: www.Tri-Conference.com • **Phone:** 781-972-5400 toll-free in the U.S.: 888-999-6288
Fax: 781-972-5425 • **Mail:** 250 First Avenue, Suite 300 Needham, MA 02494 USA

REGISTER 3 — 4TH IS FREE

Individuals must register and submit completed registration forms together for discount to apply. Please reproduce this registration form as needed.

☐ Yes! I would like a free subscription to:



1. REGISTRATION INFORMATION

☐ Mr. ☐ Ms. ☐ Mrs. ☐ Dr. ☐ Prof.

Name	Job Title
Div./Dept.	Company
Address	
City/State/Postal Code	Country
Telephone	
Would you like to receive CHI event updates via fax? ☐ Yes ☐ No Fax	
Email*	

*Email is not a mandatory field. However, by not supplying your email you will not receive pre-conference access to presenter materials, conference updates and networking opportunities.

2. PRICING INFORMATION

	Commercial	Academic, Government, Hospital-Affiliated
Track Pricing (February 28 - March 2) Access to 200+ Presentations Covering 9 Tracks, CHI's Intro-Net, Scientific Posters and More!		
Early Registration until October 27, 2006	☐ \$1495	☐ \$845
Advance Registration until January 26, 2007	☐ \$1645	☐ \$995
Registrations after January 26, 2007 and onsite	☐ \$1845	☐ \$1045

Track Selection: (REQUIRED)

CHOOSE ONE: Please indicate the one track you are most likely to attend.

- | | | |
|---|---|---|
| ☐ Track 1: Pathway Analysis | ☐ Track 4: Preclinical Development | ☐ Track 7: Clinical Trials in India & Asia |
| ☐ Track 2: R & D Strategies | ☐ Track 5: Molecular Diagnostics | ☐ Track 8: Trends in Drug Safety |
| ☐ Track 3: Mastering Medicinal Chemistry | ☐ Track 6: Stem Cell Research | ☐ Track 9: Cancer Molecular Markers |

Pre-Conference Events (February 27)

Choose 1 Short Course ☐ \$695 • Commercial ☐ \$345 • Academic, Government, Hospital-Affiliated	Choose 2 Short Courses (BEST VALUE!) ☐ \$995 • Commercial ☐ \$595 • Academic, Government, Hospital-Affiliated	Dinner ☐ \$495
Morning (check one box only) ☐ (SC1) Biotech Pharma Partnership - Part I ☐ (SC2) Global Strategies Morning Course ☐ (SC3) Novel Therapies for CNS Disorders ☐ (SC4) Microreactors ☐ (SC5) Circulating Tumor Cells ☐ (SC6) Preclinical Morning Course	Afternoon (check one box only) ☐ Biotech Pharma Partnership - Part II ☐ (SC7) Diagnostics ☐ (SC8) Biomarkers ☐ (SC9) Cancer Therapeutics ☐ (SC10) Business War Game ☐ (SC11) ADMET Case Studies ☐ (SC12) Late-PCR ☐ (SC13) Microdosing ☐ (SC14) Stem Cell Course	Evening (check one box only) ☐ (DC15) New Ways to Partner

Discounts*

- ☐ Poster (\$50 off) ☐ Alumni (25% off) ☐ BayBio Member (20% off)
- * (See pg 11 for Alumni details • Alumni and Bay Bio Discount cannot be combined • Discounts not applicable on Pre-Conference Events only registrations)

- ☐ Yes, I want to receive the Annual Biotech 2006 - Life Sciences: A Changing Prescription book by G. Steven Burrill (a \$295 value)
(To qualify you must be one of the first 50 people to register for 1 Track plus, at least 1 Short Course)

Multi-pack Discount: Purchase presentation materials for the entire event for only \$750.

CD Includes presentation material from all nine tracks, poster abstracts and more.

- ☐ I cannot attend but would like to purchase the event CD for \$750 (plus shipping) (Massachusetts delivery will include 5% sales tax).

3. PAYMENT INFORMATION

- ☐ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.
- ☐ Invoice me, but reserve my space with credit card information listed below. **Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount.** If you plan to register on site, please check with CHI beforehand for space availability.
- ☐ Please charge: ☐ AMEX (15 digits) ☐ Visa (13-16 digits) ☐ MasterCard (16 digits) ☐ Diners Club (14 digits)

Card #	Exp.Date
Cardholder Signature	
Cardholder's Address (if different from above)	
City/State/Postal Code	Country

4. FAX OR MAIL YOUR REGISTRATION TO:

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494
Phone: 781-972-5400 or toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • www.Tri-Conference.com

Cambridge Healthtech Institute

250 First Avenue, Suite 300
Needham, MA 02494



Please refer to the Registration Code below:
Keycode:

****PRESENT A POSTER AND SAVE \$50:** Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference CD, your abstract must be submitted, accepted and registration paid in full by January 23, 2007. Register online to use the Poster Abstract Submission form or, if you register by phone, fax, or mail, you will receive Poster Abstract Submission guidelines via email.

- ☐ I am interested in presenting a poster at Molecular Medicine Tri-Conference, and will submit a completed one-page abstract by January 23, 2007. (Please Note: Registration must be paid in full to present poster.)

Title

ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and a copy of the conference CD.

GROUP DISCOUNTS

Special rates are available for multiple attendees from the same organization. Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.



HANDICAPPED EQUAL ACCESS

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

SUBSTITUTION/CANCELLATION POLICY

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization
- Credit your registration to another Cambridge Healthtech Institute program
- Request a refund minus a \$100 processing fee per conference
- Request a refund minus the cost (\$750) of ordering a copy of the CD

NOTE: Cancellations will only be accepted up to two weeks prior to the conference.

Program and speakers are subject to change.

Video and/or audio recording of any kind is prohibited onsite at all CHI events.